文献速递中医内科中药与中成药合理使用

醒脑静注射液治疗脑梗死临床评价的Meta分析

Meta-Analysis for Clinical Evaluation of Xingnaojing Injection for the Treatment of Cerebral Infarction.
PubMed 文献 · Front Pharmacol · 2017-08-29

该Meta分析纳入53项随机对照试验共4915例脑梗死患者,评价醒脑静注射液(XNJ)的疗效。结果显示,与单纯常规治疗相比,XNJ可显著提高总有效率、改善日常生活活动能力、缩小梗死体积、降低神经功能缺损评分,并改善血液流变学和血脂,但格拉斯哥昏迷评分无显著差异。结论认为XNJ可能是有益的治疗方法,但受纳入研究样本量和质量限制。

要点

  • XNJ联合常规治疗可提高脑梗死总有效率(OR=3.56)。
  • XNJ可改善ADL、缩小梗死体积、降低NIHSS和CSS评分。
  • XNJ对GCS无显著改善,证据质量受限于原始研究。

核心结论

  • 与单纯常规治疗相比,醒脑静注射液可能对脑梗死患者有益,但受纳入研究样本量和质量限制。

研究设计与样本

  • Meta分析检索了CBM、万方、维普、CNKI、PubMed、Embase和Cochrane Library共6个数据库,纳入2016年11月26日前评估XNJ治疗脑梗死临床疗效的随机对照试验。
  • 共纳入53项随机对照试验,涉及4915名参与者。

主要发现

  • 与单纯常规治疗相比,XNJ显著提高总有效率(OR=3.56,95%CI [2.94, 4.32],P<0.00001)。
  • XNJ显著增加日常生活活动能力(ADL,MD=10.23,95%CI [9.47, 10.99],P<0.00001),缩小梗死体积(MD=-1.83,95%CI [-2.49, -1.16],P<0.00001)。
  • XNJ与常规治疗在格拉斯哥昏迷评分(GCS)上无显著差异(P=0.32)。
  • XNJ显著降低NIHSS评分(MD=-3.44,95%CI [-4.52, -2.36],P<0.00001)和CSS评分(MD=-5.72,95%CI [-6.94, -4.50],P<0.00001)。
  • XNJ显著降低血清MMP-2(MD=-11.24,95%CI [-20.83, -1.65],P=0.02)和MMP-9(MD=-25.08,95%CI [-35.49, -14.67],P<0.00001)。

临床怎么用

  • 在常规治疗基础上,可考虑联合醒脑静注射液以改善脑梗死患者的总体反应率、日常生活活动能力和神经功能缺损。
  • 醒脑静注射液可能有助于缩小梗死体积和改善血液流变学,但需结合患者具体情况使用。
  • 因原始研究质量有限,临床应用应谨慎评估获益与风险。

局限性

  • 纳入研究的样本量和质量较差,可能影响结论的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Xingnaojing injection (XNJ) is derived from An-Gong-Niu-Huang pill, a well-known traditional Chinese patent medicine, which is widely used for stroke. To evaluate the therapeutic effect of XNJ on cerebral infarction, an extensive meta-analysis was used. Methods: Six major electronic databases including the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine information system (VMIS) and the China National Knowledge Infrastructure (CNKI), PubMed, Embase, and the Cochrane Library were examined to retrieve randomized controlled trials designed to evaluate the clinical efficacy of XNJ in treating CI before November 26, 2016. Results: There were 53 randomized controlled trials with 4915 participants in this study. The results reflected that compared with the conventional therapy (CT) alone, XNJ could significantly improve the overall response rate (OR = 3.56, 95% CI [2.94, 4.32], P < 0.00001), and clinical symptom (including increasing activities of daily living (ADL, MD = 10.23, 95% CI [9.47, 10.99], P < 0.00001), and reduce infarction size (MD = -1.83, 95% CI [-2.49, -1.16], P < 0.00001)). However, there was no significant difference between the XNJ treatment and conventional therapy in Glasgow Coma Scale (GCS, P = 0.32). Neurological deficit score demonstrated that XNJ could significantly reduce the score in two different evaluation criterions as National Institutes of Health Stroke Scale (NIHSS, MD = -3.44, 95% CI [-4.52, -2.36], P < 0.00001), and the Chinese Stroke Scale (CSS, MD = -5.72, 95% CI [-6.94, -4.50], P < 0.00001). Additionally, serum MMPs, including MMP-2 and MMP-9 were significantly reduced by XNJ treatment compared with conventional therapy (MD = -11.24, 95% CI [-20.83, -1.65], P = 0.02; MD = -25.08, 95% CI [-35.49, -14.67], P < 0.00001, respectively). Moreover, XNJ was able to improve hemorrheology in reducing whole blood viscosity, plasma viscosity, and hematocrit (MD = -1.44, 95% CI [-2.18, 0.70], P = 0.001; MD = -0.22, 95% CI [-0.37, -0.07], P = 0.003; MD = -3.63, 95% CI [-6.23, -1.03], P = 0.006, respectively). The therapeutic efficacy of XNJ was found associated with improving hemodynamics (increasing peak-flow rate, and average velocity) (MD = 12.66, 95% CI [10.50, 14.81], P < 0.00001; MD = 9.90, 95% CI [8.63, 11.17], P < 0.00001). XNJ was also related to reducing cholesterol and triglyceride (MD = -1.06, 95% CI [-1.21, -0.92], P < 0.00001; MD = -1.05, 95% CI [-1.12, -0.97], P < 0.00001). Conclusion: Despite the sample size and the poor quality of the included studies of this review, the results of the research showed that XNJ might be a beneficial therapeutic method for the treatment of cerebral infarction.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ma X, Yang YX, Chen N, et al. Meta-Analysis for Clinical Evaluation of Xingnaojing Injection for the Treatment of Cerebral Infarction. Front Pharmacol. 2017. PMID: 28912713. doi:10.3389/fphar.2017.00485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。